// App-Quantinova.ai

LBA-1 : First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study

Researchers

Presenter

  • Z. Wainberg

Principal Investigators

  • T. Bekaii-Saab

  • P. Boland

  • F. Dayyani

  • T. Macarulla

  • K. Mody

  • B. Belanger

  • F. Maxwell

  • Y. Moore

  • A. Thiagalingam

  • T. Wang

  • B. Zhang

  • A. Dean

Medical Centers

  • University of California at Los Angeles, Los Angeles, California, United States

  • Mayo Clinic, Phoenix, Arizona, United States

  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

  • University of California, Davis, Davis, California, United States

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Mayo Clinic, Jacksonville, Jacksonville, Florida, United States

  • Biogen, Cambridge, United States

  • Ipsen, Abingdon, Oxfordshire, United Kingdom

  • Department of Oncology, St John of God Subiaco Hospital, Subiaco, Australia

Locations

  • United States

  • Spain

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Irinotecan

  • Fluorouracil

  • Adrucil injection

  • Oxaliplatin

  • leucovorin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved